Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Human metabolism of the experimental cancer therapeutic agent d-limonene.

Crowell PL, Elson CE, Bailey HH, Elegbede A, Haag JD, Gould MN.

Cancer Chemother Pharmacol. 1994;35(1):31-7.

PMID:
7987974
2.

Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC.

Cancer Chemother Pharmacol. 1998;42(2):111-7.

PMID:
9654110
3.
4.

Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry.

Poon GK, Vigushin D, Griggs LJ, Rowlands MG, Coombes RC, Jarman M.

Drug Metab Dispos. 1996 May;24(5):565-71.

PMID:
8723738
5.

Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth.

Crowell PL, Lin S, Vedejs E, Gould MN.

Cancer Chemother Pharmacol. 1992;31(3):205-12.

PMID:
1464157
6.

R-Limonene metabolism in humans and metabolite kinetics after oral administration.

Schmidt L, Göen T.

Arch Toxicol. 2017 Mar;91(3):1175-1185. doi: 10.1007/s00204-016-1751-6. Epub 2016 Jun 21.

PMID:
27325307
7.

Gas chromatographic-mass spectrometric analysis of d-limonene in human plasma.

Wang S, Chen Y, Gao Z, Xiong M, Zhong Z, Ye L.

J Pharm Biomed Anal. 2007 Sep 3;44(5):1095-9. Epub 2007 Apr 22.

PMID:
17540528
8.

Pharmacokinetics of d-limonene in the rat by GC-MS assay.

Chen H, Chan KK, Budd T.

J Pharm Biomed Anal. 1998 Aug;17(4-5):631-40.

PMID:
9682146
9.

Inhibition of protein prenylation by metabolites of limonene.

Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, Jarman M.

Biochem Pharmacol. 1999 Apr 1;57(7):801-9.

PMID:
10075086
10.
11.

Bioequivalence evaluation of two D-limonene capsule formulations in healthy Chinese volunteers.

Liu T, Guo Y, Gao Z, Chen Z, Jiang X.

Pharmazie. 2008 Oct;63(10):718-20.

PMID:
18972832
12.

Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.

Zhang Z, Chen H, Chan KK, Budd T, Ganapathi R.

J Chromatogr B Biomed Sci Appl. 1999 May 14;728(1):85-95.

PMID:
10379660
13.

Distribution and immune responses resulting from oral administration of D-limonene in rats.

Hamada M, Uezu K, Matsushita J, Yamamoto S, Kishino Y.

J Nutr Sci Vitaminol (Tokyo). 2002 Apr;48(2):155-60.

PMID:
12171437
14.

Adipose tissue accumulation of d-limonene with the consumption of a lemonade preparation rich in d-limonene content.

Miller JA, Hakim IA, Chew W, Thompson P, Thomson CA, Chow HH.

Nutr Cancer. 2010;62(6):783-8. doi: 10.1080/01635581003693066.

PMID:
20661827
15.

d-limonene exposure to humans by inhalation: uptake, distribution, elimination, and effects on the pulmonary function.

Falk-Filipsson A, Löf A, Hagberg M, Hjelm EW, Wang Z.

J Toxicol Environ Health. 1993 Jan;38(1):77-88.

PMID:
8421324
16.

The fate of dermally applied [14C]d-limonene in rats and humans.

Api AM, Ritacco G, Hawkins DR.

Int J Toxicol. 2013 Mar-Apr;32(2):130-5. doi: 10.1177/1091581813479979. Epub 2013 Mar 14.

PMID:
23493903
17.

Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer.

Miller JA, Lang JE, Ley M, Nagle R, Hsu CH, Thompson PA, Cordova C, Waer A, Chow HH.

Cancer Prev Res (Phila). 2013 Jun;6(6):577-84. doi: 10.1158/1940-6207.CAPR-12-0452. Epub 2013 Apr 3.

18.

d-Limonene-induced male rat-specific nephrotoxicity: evaluation of the association between d-limonene and alpha 2u-globulin.

Lehman-McKeeman LD, Rodriguez PA, Takigiku R, Caudill D, Fey ML.

Toxicol Appl Pharmacol. 1989 Jun 15;99(2):250-9.

PMID:
2472019
19.
20.

Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites.

Crowell PL, Chang RR, Ren ZB, Elson CE, Gould MN.

J Biol Chem. 1991 Sep 15;266(26):17679-85.

Supplemental Content

Support Center